Loading patent…
AssigneeWellstat Biologics Corporation
InventorsJohn Bell, Nahum Sonenberg, David Stojdl, Earl Brown, Harold Atkins, Ricardo Marius, Brian Lichty, Shane Knowles
Estimating the term…
The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR−/−, STAT1−/− or both PKR−/− and STAT1−/−. The virus is selected from the group consisting of Rhabdovirus and picomavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.
A method of reducing the viability of a tumor cell, comprising administering to the tumor cell an attenuated strain of vesicular stomatitis virus, wherein said tumor cell is a carcinoma.
A method of reducing the viability of a tumor cell within a population of tumor cells and non-tumor cells comprising administering an attenuated strain of vesicular stomatitis virus to the population of cells, wherein tumor cells are carcinoma cells and the virus is able to selectively infect and kill the tumor cell.
Dependencies are inferred from the claim text.